OIPE vo	g) <u>e</u> ,					JFW	
MAY 0 5 2005	5-1	TRANSMITTAL LETTER (General - Patent Pending)				cket No. 60/1/US	
In Re Application Of: Hagen et al.							
Application No.	Filing Date	Exa	miner	Customer No.	Group Art Unit	Confirmation No.	
10/623,228	July 18, 2003	Sto	ckton	26648	1626	2720	
Title: SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION							
COMMISSIONER FOR PATENTS:							
Transmitted herewith is:							
Combined Ame	endment/Extension of Ti mized Postcard.	me Transmitt:	al; Amendment A	.; Copy of U.S. 1	Provisional Appli	cation No.	
in the above ide	ntified application.						
☐ No addition	nal fee is required.						
	the amount of		attached.	A A NI-	10 1035		
	tor is hereby authorized eed below	to cnarge an	a creati Deposit	Account No.	19-1025		
	harge the amount of	\$450.00					
⊠ C	redit any overpayment.						
	harge any additional fee	-					
	 Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be 						

included on this form. Provide credit card information and authorization on PTO-2038.

Patricia K. Fitzsimmons, Reg. No. 52,894 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027

Chesterfield, Missouri 63006

314.274.1490

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box

1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

May 3, 2005

Dated: May 3, 2005

Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

MAY 0 5 2005 T		ocket No. 60/1/US				
	n Of: Timothy J. Hage	en et al.				
Application No.	Filing Date	Examiner	Customer No	. Grou	p Art Unit	Confirmation
10/623,228	July 18, 2003	Laura L. Stockton	26648	1	626	2720
INF	FLAMMATION					
		COMMISSIONER FOR	s of 37 CFR 1.136(tend the p	eriod for filing a
·		cember 3, 2004 in the al	• •	lication.		
•	•	check time period desire				
☐ One m	onth 🖾 Two me	onths Three m	nonths 🗆 Foui	r months	, 🗆	Five months
from:	March 3, 2009 Date	5 until:	<u></u>	Date	05	
	Date	sion of time has been cal		Date	05	
	Date		lculated as shown b	Date	05	
	Date	sion of time has been cal	lculated as shown b	Date pelow:		ADDITIONAL
	Date amendment and extens	CLAIMS AS AME	culated as shown b	Date		ADDITIONAL FEE
	Date amendment and extens CLAIMS REMAINING	CLAIMS AS AME	Iculated as shown b ENDED NUMBER EXTRA	Date Delow: RAT		
The fee for the a	Date Amendment and extens CLAIMS REMAINING AFTER AMENDMENT	CLAIMS AS AME HIGHEST # PREV. PAID FOR	culated as shown be ENDED NUMBER EXTRA CLAIMS PRESENT	Date Delow:	E	FEE \$0
The fee for the a	Date Amendment and extens CLAIMS REMAINING AFTER AMENDMENT 15 -	CLAIMS AS AME HIGHEST # PREV. PAID FOR 69 =	ENDED NUMBER EXTRA CLAIMS PRESENT 0	Date Pelow: RAT X \$2	E 650.00 200.00	FEE \$0.
The fee for the a	Date Amendment and extens CLAIMS REMAINING AFTER AMENDMENT 15 -	CLAIMS AS AME HIGHEST # PREV. PAID FOR 69 = 1 =	ENDED NUMBER EXTRA CLAIMS PRESENT 0 0	Date Pelow: RAT X S X MENDM	E 550.00 200.00	\$0. \$0.
The fee for the a	CLAIMS REMAINING AFTER AMENDMENT 15 - 1 -	CLAIMS AS AME HIGHEST # PREV. PAID FOR 69 = 1 =	ENDED NUMBER EXTRA CLAIMS PRESENT 0 0 FEE FOR A	Date Pelow: RAT X S MENDM ON OF	E 650.00 200.00 IENT	\$0 \$0 \$0 \$0 \$450
The fee for the a	CLAIMS REMAINING AFTER AMENDMENT 15 - 1 -	CLAIMS AS AME HIGHEST # PREV. PAID FOR 69 = 1 =	ENDED NUMBER EXTRA CLAIMS PRESENT 0 0 FEE FOR A	Date Pelow: RAT X S MENDM ON OF	E 650.00 200.00 IENT	\$0 \$0 \$0 \$0 \$450
The fee for the a	CLAIMS REMAINING AFTER AMENDMENT 15 - 1 -	CLAIMS AS AME HIGHEST # PREV. PAID FOR 69 = 1 =	ENDED NUMBER EXTRA CLAIMS PRESENT 0 0 FEE FOR A	Date Pelow: RAT X S MENDM ON OF	E 650.00 200.00 IENT	FEE

COMBINED AMENDMENT & PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) (Large Entity)

Docket No. **01160/1/US**

The	e fee for the amendment and extension of ti	ime is to be	paid as follows:	
	A check in the amount of	for the a	mendment and exte	nsion of time is enclosed.
\boxtimes	Please charge Deposit Account No.	19-1025	in the amount of	\$450.00
X	The Director is hereby authorized to charge communication or credit any overpayment		_	s associated with this
	☐ Any additional filing fees required ur☒ Any patent application processing fe			
\boxtimes	If an additional extension of time is required to Deposit Ac		onsider this a petitio	on therefor and charge any additional
	Payment by credit card. Form PTO-2038 WARNING: Information on this form m included on this form. Provide credit c	ay become		
	Patrial Phrimeer		Dated:	May 3, 2005
Patrici	ia K. Fitzsimmons, Reg. No. 52,894 nacia Corporation of Pfizer Inc.		l hereby deposited	certify that this correspondence is being I with the United States Postal Service with

May 3, 2005

(Gate)

Signature of Person Mailing Correspondence

Linda K. Cooper

sufficient postage as first class mail in an envelope

addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

Typed or Printed Name of Person Mailing Correspondence

P.O. Box 1027

314.274.1490

Chesterfield, Missouri 63006

Docket No. TRANSMITTAL LETTER (General - Patent Pending) 01160/1/US In Re Application Of: Hagen et al. Customer No. Group Art Unit Filing Date Examiner Application No. July 18, 2003 26648 1626 10/623,228 Stockton SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF Title: **INFLAMMATION COMMISSIONER FOR PATENTS:** Transmitted herewith is: Form 1449; Information Disclosure; Itemized Postcard. in the above identified application. No additional fee is required.

The Director is hereby authorized to charge and credit Deposit Account No.

19-1025

as described below.

A check in the amount of

 \boxtimes Charge the amount of \$180.00

Credit any overpayment. \boxtimes

Charge any additional fee required.

☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

is attached.

Dated: May 3, 2005

Patricia K. Fitzsimmons, Reg. No. 52,894 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.1490

hereby certify that this correspondence deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

May 3, 2005

gnature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

CC:

Confirmation No.

2720